Updated:
Genalyte
Get real-time lab results in under 30 minutes without leaving your clinic. Genalyte’s on-site platform makes blood testing faster, easier, and more reliable.
Genalyte
Get real-time lab results in under 30 minutes without leaving your clinic. Genalyte’s on-site platform makes blood testing faster, easier, and more reliable.
General information
Firm type
other
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
What does Genalyte's Merlin device do?
Merlin is a self-running diagnostic instrument that performs chemistry, hematology, and immunoassay testing on a single platform, returning results within 30 minutes. It integrates with electronic medical records to eliminate manual data entry and labeling errors.
How does Genalyte's platform reduce lab errors?
Genalyte claims that 68% of all lab mistakes occur before analysis due to logistics and data handling. Merlin's direct EMR integration and automated routing remove manual steps, reducing pre-analytical errors.
What clinical setting is Genalyte targeting?
Genalyte markets Merlin to primary care clinics, urgent care centers, and hospital outpatient departments. The device is designed to fit into existing workflows without dedicated lab staff, enabling same-visit testing.
Does Genalyte disclose its ownership or funding?
Genalyte does not publicly list its investors, ownership structure, or key executives. The company's website focuses entirely on the Merlin device and its clinical benefits without financial or corporate information.
What is the Maverick Immunoassay Analyser?
Maverick is Genalyte's proprietary immunoassay analyzer integrated into the Merlin platform. It enables rapid detection of biomarkers alongside standard chemistry and hematology tests in a single device.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: